ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.
Synonyms: Class E basic helix-loop-helix protein 39; Myc proto-oncogene protein; Proto-oncogene c-Myc; Transcription factor p64; bHLHe39
Storage: 2-8C
Application: Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected c-Myc in human kidney, mouse testis, and human cervical cancer tissue sections.RNAi/siRNA/Gene Knockdown Analysis: A 1:1000 dilution from a representative lot detected c-Myc in lysate from wild-type HEK293 cells, but not in HEK293 cells with c-myc knocked out using CRISPR. Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected Myc proto-oncogene protein in HeLa, A431, HUVEC, and NIH 3T3 cell lines.
Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany